Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04646239 · ClinicalTrials.gov registry record

Biomarkers of Trained Immunity Following MMR Vaccination

A clinical trial, sponsored by Washington University School of Medicine.

Completed
Registry status
96
Enrollment target

NCT04646239: Completed study, sponsored by Washington University School of Medicine.

NCT04646239 is a clinical trial that has completed, run by Washington University School of Medicine. The registered enrollment target is 96 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04646239 has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
96 participants
Enrollment target

Study Summary

This is a substudy of NCT04333732. The goal of this sub-study is to identify and characterize biomarkers of trained immunity by measuring, in vitro, immune responses to heterologous products, especially viral associated products, in the MMR vaccinated compared placebo groups. All participants are randomly assigned to MMR or placebo injection at baseline, followed by SARS-CoV-2 specific vaccination. Blood is drawn around 60 to 90 days after the last SARS-CoV-2 specific vaccine injection.

Primary Outcome

Cytokines such as TNF-α, IL-1β and IL-6 produced by human monocytes, and IFN-γ produced by natural killer (NK)-cells, are markers of trained immunity and these (and other cytokines and chemokines) will be measured in supernatants of stimulated PBMCs from a cohort of participants in the CROWN CORONATION trial. All cytokines and chemokines are measured in picograms/milliliter.

Interventions

  • DIAGNOSTIC_TEST Heterologous stimuli
  • DIAGNOSTIC_TEST Neutralization assay

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2020-12-17
Est. Completion 2021-06-28

What the finished NCT04646239 record still lists

NCT04646239 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 96 participants, a relatively small participant target.

The record links to 0 conditions, and to 2 interventions - of which Heterologous stimuli is the first listed.

NCT04646239 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04646239 about?

NCT04646239 is a clinical study titled "Biomarkers of Trained Immunity Following MMR Vaccination". This is a substudy of NCT04333732. The goal of this sub-study is to identify and characterize biomarkers of trained immunity by measuring, in vitro, immune responses to heterologous products, especially viral associated products, in the MMR vaccinated compared placebo groups. All participants are r...

What is the current status of trial NCT04646239?

This trial is currently completed. The enrollment target is 96 participants. The study started on 2020-12-17. Estimated completion is 2021-06-28.

What interventions are being tested in trial NCT04646239?

The interventions under investigation include: Heterologous stimuli (DIAGNOSTIC_TEST), Neutralization assay (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04646239?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03401762 · 96 participants · NA

    Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke

  • NCT03471260 · 96 participants · Phase 1

    Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • NCT03549559 · 96 participants · NA

    Imaging Histone Deacetylase in the Heart

  • NCT03841058 · 96 participants · Phase 2

    Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04646239, the US trial registry maintained by the National Library of Medicine. NCT04646239 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.